Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 489,949
  • Shares Outstanding, K 157,540
  • Annual Sales, $ 54,520 K
  • Annual Income, $ -16,740 K
  • 36-Month Beta 0.90
  • Price/Sales 8.07
  • Price/Cash Flow N/A
  • Price/Book 20.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.02
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.04
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.53 +20.16%
on 12/28/18
3.20 -5.00%
on 01/09/19
+0.02 (+0.66%)
since 12/14/18
3-Month
2.53 +20.16%
on 12/28/18
3.78 -19.58%
on 11/06/18
-0.49 (-13.88%)
since 10/16/18
52-Week
1.85 +64.32%
on 02/06/18
3.93 -22.65%
on 10/02/18
+0.82 (+36.94%)
since 01/16/18

Most Recent Stories

More News
Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company's Board of Directors

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Peter S. Greenleaf to the Company's Board of Directors. Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently...

BDSI : 4.21 (+1.45%)
ATRS : 3.06 (-0.33%)
CERC : 4.64 (+7.41%)
Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Antares Pharma, Inc. (NASDAQ:ATRS),...

ECA : 6.90 (+0.29%)
PPG : 102.66 (+1.64%)
CATO : 14.71 (-0.54%)
XEC : 73.55 (+0.31%)
ATRS : 3.06 (-0.33%)
ORA : 53.95 (+0.60%)
Antares Pharma Announces the Commercial Availability of XYOSTED(TM) (Testosterone Enanthate) Injection -- A New Treatment for Adult Men Diagnosed With Testosterone Deficiency

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of XYOSTED(TM) (testosterone enanthate) injection. XYOSTED(TM) is the only FDA approved subcutaneous testosterone product for once-weekly,...

ATRS : 3.06 (-0.33%)
Teva (TEVA) Launches First Generic Version of Mylan's EpiPen

Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.

MYL : 29.45 (+0.34%)
ADMP : 2.57 (+2.39%)
ATRS : 3.06 (-0.33%)
TEVA : 18.91 (+0.42%)
Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen(R)

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that Teva Pharmaceutical Industries, Ltd.'s ("Teva") generic EpiPen is now commercially available in limited quantities. Teva's generic EpiPenwas...

ATRS : 3.06 (-0.33%)
Antares Pharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 30 Annual Piper Jaffray Healthcare Conference on Tuesday, November 27,...

ATRS : 3.06 (-0.33%)
Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. (Nasdaq: ATRS) have filed a class action complaint against the company's officers and...

ATRS : 3.06 (-0.33%)
Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting

XYOSTED(TM) AMBULATORY BLOOD PRESURE ABSTRACT HAS BEEN SELECTED FOR POSTER PRESENTATION

ATRS : 3.06 (-0.33%)
Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Thursday November 15,...

ATRS : 3.06 (-0.33%)
Antares Pharma: 3Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported a loss of $1.9 million in its third quarter.

ATRS : 3.06 (-0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATRS with:

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Key Turning Points

2nd Resistance Point 3.17
1st Resistance Point 3.12
Last Price 3.06
1st Support Level 2.99
2nd Support Level 2.91

See More

52-Week High 3.93
Fibonacci 61.8% 3.14
Last Price 3.06
Fibonacci 50% 2.89
Fibonacci 38.2% 2.64
52-Week Low 1.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar